Filtrer vos résultats
- 3
- 3
- 3
- 1
- 1
- 1
- 3
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
|
Efficacy and Safety of Erythropoietic-Stimulating Agents with Ruxolitinib in Myelofibrosis Patients : A Retrospective Analysis on 45 Patients. on Behalf of the French Intergroup of Myeloproliferative Disorders (FIM)Blood, 2016, 128 (22), ⟨10.1182/blood.V128.22.3123.3123⟩
Article dans une revue
hal-03605650v1
|
||
|
A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic ChemotherapyOncologist, 2021, 26 (10), pp.E1870-E1879. ⟨10.1002/onco.13888⟩
Article dans une revue
hal-03598654v1
|
||
Brain radiotherapy in patients treated for a newly diagnosed primary central nervous system lymphoma: professional practice evaluation in 19 French centersActa Oncologica, 2023, pp.1-9. ⟨10.1080/0284186X.2023.2225146⟩
Article dans une revue
hal-04137809v1
|